阿托伐他汀治疗冠心病合并高脂血症的可行性及安全性  

Analysis of the Feasibility and Safety of Atorvastatin for the Treatment of Coronary Artery Disease Complicated by Hyperlipidemia

作　　者：叶千琼 

机构地区：[1]四川省南江县人民医院内七科,四川南江636600

出　　处：《中外医疗》2015年第2期16-17,共2页China & Foreign Medical Treatment

摘　　要：目的探讨阿托伐他汀治疗冠心病合并高脂血症的有效性和安全性。方法选取2013年1月—2014年3月该院收治的420例冠心病合并高脂血症患者,按照随机数字表法均分为对照组和观察组,对照组给予血脂康口服,观察组给予阿托伐他汀钙片口服,随访8周,比较两组患者治疗前后TC、TG、LDL-C、HDL-C、治疗总有效率和不良反应发生率的差异。结果治疗8周后,观察组TC、TG、LDL-C均显著低于对照组(P<0.05),HDL-C高于对照组(P<0.05);观察组治疗总有效率为93.3%,高于对照组的83.8%(P<0.05);两组患者均无严重不良反应发生(P>0.05)。结论阿托伐他汀治疗冠心病合并高脂血症效果确切,可有效改善血脂,延缓动脉粥样硬化,无严重不良反应。Objective To investigate the clinical efficacy and safety of Atorvastatin for coronary artery disease and hyperlipidemia. Methods 420 cases with coronary artery disease and hyperlipidemia admitted in this hospital from January 2013 to March 2014 were randomly divided into control group and observation group. The control group were treated with Xuezhikang orally, and the observation group were treated with Atorvastatin calcium tablets orally. All the patients were followed for 8 weeks. And the TC, TG, LDL-C, HDL-C, total effective rate and adverse reaction rate of two groups before and after treatment were compared. Results After 8 weeks of treatment, the levels of TC, TG and LDL-C of the observation group were much lower than those of the control group （P〈0.05）, while the level of HDL-C was higher than that of the control group（P〈0.05）;the total effective rate of the observa-tion group was 93.3%, higher than 83.8% of the control group （P〈0.05）. And no severe adverse reactions occurred in both groups （P〉0.05）. Conclusion For coronary artery disease and hyperlipidemia, Atorvastatin has exact effect. It can effectively improve the blood lipids and anti-atherosclerosis without serious adverse reactions.

关 键 词：阿托伐他汀 冠心病 高脂血症 

分 类 号：R541.4[医药卫生—心血管疾病]